Table 3.
Placebo | 150 mg | 200 mg | ||
Sarilumab MOBILITY Study, part B42 Genovese et al. |
ACR 20 | 33% | 58% | 66% |
ACR 50 | 17% | 37% | 46% | |
ACR 70 | 7% | 20% | 25% | |
Placebo | 4 mg/kg | 8 mg/kg | ||
Tocilizumab OPTION Study29 Smolen et al. |
ACR 20 | 26% | 48% | 59% |
ACR 50 | 11% | 32% | 11% | |
ACR 70 | 2% | 12% | 22% | |
Placebo | 4 mg/kg | 8 mg/kg | ||
Tocilizumab LITHE Study28 Kremer et al. |
ACR 20 | 27% | 51% | 56% |
ACR 50 | 10% | 25% | 32% | |
ACR 70 | 2% | 11% | 13% |